Journal article
Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial
- Abstract:
-
BACKGROUND:There is an urgent need for an effective tuberculosis (TB) vaccine. Heterologous prime-boost regimens induce potent cellular immunity. MVA85A is a candidate TB vaccine. This phase I clinical trial was designed to evaluate whether alternating aerosol and intradermal vaccination routes would boost cellular immunity to the Mycobacterium tuberculosis antigen 85A (Ag85A). METHODS AND FINDINGS:Between December 2013 and January 2016, 36 bacille Calmette-Guérin-vaccinated, healthy UK adult...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Bibliographic Details
- Publisher:
- Public Library of Science Publisher's website
- Journal:
- PLoS Medicine Journal website
- Volume:
- 16
- Issue:
- 4
- Pages:
- e1002790
- Publication date:
- 2019-04-30
- Acceptance date:
- 2019-03-26
- DOI:
- EISSN:
-
1549-1676
- ISSN:
-
1549-1277
- Pmid:
-
31039172
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:995629
- UUID:
-
uuid:d0fd4c71-8b3c-4b81-8a29-6f5b029f5216
- Local pid:
- pubs:995629
- Source identifiers:
-
995629
- Deposit date:
- 2019-05-09
Terms of use
- Copyright holder:
- Thomas et al
- Copyright date:
- 2019
- Notes:
- © 2019 Manjaly Thomas et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
- Licence:
- CC Attribution (CC BY)
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record